{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T10:50:19Z","timestamp":1792839019434,"version":"4.5.0"},"reference-count":181,"publisher":"MDPI AG","issue":"23","license":[{"start":{"date-parts":[[2022,12,6]],"date-time":"2022-12-06T00:00:00Z","timestamp":1670284800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Ovarian cancer is the eighth most common neoplasm in women with a high mortality rate mainly due to a marked propensity for peritoneal spread directly at diagnosis, as well as tumor recurrence after radical surgical treatment. Treatments for peritoneal metastases have to be designed from a patient\u2019s perspective and focus on meaningful measures of benefit. Hyperthermic intraperitoneal chemotherapy (HIPEC), a strategy combining maximal cytoreductive surgery with regional chemotherapy, has been proposed to treat advanced ovarian cancer. Preliminary results to date have shown promising results, with improved survival outcomes and tumor regression. As knowledge about the disease process increases, practice guidelines will continue to evolve. In this review, we have reported a broad overview of advanced ovarian cancer management, and an update of the current evidence. The future perspectives of the Italian Society of Surgical Oncology (SICO) are discussed conclusively.<\/jats:p>","DOI":"10.3390\/cancers14236010","type":"journal-article","created":{"date-parts":[[2022,12,7]],"date-time":"2022-12-07T04:00:37Z","timestamp":1670385637000},"page":"6010","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Cytoreductive Surgery (CRS) and HIPEC for Advanced Ovarian Cancer with Peritoneal Metastases: Italian PSM Oncoteam Evidence and Study Purposes"],"prefix":"10.3390","volume":"14","author":[{"given":"Daniele","family":"Marrelli","sequence":"first","affiliation":[{"name":"Unit of General Surgery and Surgical Oncology, Department of Medicine, Surgery and Neurosciences, University of Siena, 53100 Siena, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Ansaloni","sequence":"additional","affiliation":[{"name":"Unit of General Surgery San Matteo Hospital, 27100 Pavia, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Orietta","family":"Federici","sequence":"additional","affiliation":[{"name":"Peritoneal Tumors Unit, IRCCS Regina Elena National Cancer Institute, 00144 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8958-621X","authenticated-orcid":false,"given":"Salvatore","family":"Asero","sequence":"additional","affiliation":[{"name":"Unit of Surgical Oncology, Soft Tissue Tumors, Department of Oncology, Azienda Ospedaliera di Rilievo Nazionale e di Alta Specializzazione Garibaldi, 95123 Catania, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2862-6788","authenticated-orcid":false,"given":"Ludovico","family":"Carbone","sequence":"additional","affiliation":[{"name":"Unit of General Surgery and Surgical Oncology, Department of Medicine, Surgery and Neurosciences, University of Siena, 53100 Siena, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9777-9588","authenticated-orcid":false,"given":"Luigi","family":"Marano","sequence":"additional","affiliation":[{"name":"Unit of General Surgery and Surgical Oncology, Department of Medicine, Surgery and Neurosciences, University of Siena, 53100 Siena, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2402-2178","authenticated-orcid":false,"given":"Gianluca","family":"Baiocchi","sequence":"additional","affiliation":[{"name":"Department of Clinical and Experimental Sciences, University of Brescia, ASST Spedali Civili, 25123 Brescia, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Vaira","sequence":"additional","affiliation":[{"name":"Candiolo Cancer Institute, FPO\u2013IRCCS, Candiolo, 10060 Torino, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federico","family":"Coccolini","sequence":"additional","affiliation":[{"name":"General, Emergency and Trauma Surgery, Pisa University Hospital, 56122 Pisa, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Di Giorgio","sequence":"additional","affiliation":[{"name":"Surgical Unit of Peritoneum and Retroperitoneum, Fondazione Policlinico Universitario A. Gemelli\u2013IRCCS, 00168 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimo","family":"Framarini","sequence":"additional","affiliation":[{"name":"Surgery and Advanced Oncological Therapy Unit, Ospedale GB. Morgagni-L. Pierantoni, AUSL Forl\u00ec, 47121 Forl\u00ec-Cesena, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8471-710X","authenticated-orcid":false,"given":"Roberta","family":"Gelmini","sequence":"additional","affiliation":[{"name":"Unit of Emergency General Surgery and Surgical Oncology, AOU Policlinico di Modena, 41125 Modena, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmen","family":"Palopoli","sequence":"additional","affiliation":[{"name":"Unit of PSG and OBI, Azienda Ospedaliera Universitaria G. Martino, 98124 Messina, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabio","family":"Accarpio","sequence":"additional","affiliation":[{"name":"CRS and HIPEC Unit, Pietro Valdoni, Umberto I Policlinico di Roma, 00161 Roma, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Fagotti","sequence":"additional","affiliation":[{"name":"Unit of Ovarian Carcinoma, Fondazione Policlinico Universitario A. Gemelli\u2013IRCCS, 00168 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,12,6]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"vi24","DOI":"10.1093\/annonc\/mdt333","article-title":"Newly Diagnosed and Relapsed Epithelial Ovarian Carcinoma: ESMO Clinical Practice Guidelines for Diagnosis, Treatment and Follow-Up","volume":"24","author":"Ledermann","year":"2013","journal-title":"Ann. Oncol. Off. J. Eur. Soc. Med. Oncol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"9","DOI":"10.20892\/j.issn.2095-3941.2016.0084","article-title":"Epidemiology of Ovarian Cancer: A Review","volume":"14","author":"Reid","year":"2017","journal-title":"Cancer Biol. Med."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1007\/s11912-020-00933-8","article-title":"First-Line Management of Advanced High-Grade Serous Ovarian Cancer","volume":"22","author":"Mahmood","year":"2020","journal-title":"Curr. Oncol. Rep."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"394","DOI":"10.3322\/caac.21492","article-title":"Global Cancer Statistics 2018: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries","volume":"68","author":"Bray","year":"2018","journal-title":"CA Cancer J. Clin."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1016\/j.ygyno.2015.06.017","article-title":"Why Have Ovarian Cancer Mortality Rates Declined? Part I. Incidence","volume":"138","author":"Sopik","year":"2015","journal-title":"Gynecol. Oncol."},{"key":"ref_6","unstructured":"National Cancer Institute (NIH) (2022, June 22). Cancer Stat Facts: Ovaria Cancer, Available online: https:\/\/seer.cancer.gov\/statfacts\/html\/ovary.html."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"280","DOI":"10.3322\/caac.21559","article-title":"Epithelial Ovarian Cancer: Evolution of Management in the Era of Precision Medicine","volume":"69","author":"Lheureux","year":"2019","journal-title":"CA Cancer J. Clin."},{"key":"ref_8","unstructured":"Reid, F. (2020). World Ovarian Cancer Coalition Atlas. 2020. Global Trends in Incidence, Mortality, and Survival, World Ovarian Cancer Coalition."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1097\/IGC.0000000000000675","article-title":"Restaging and Survival Analysis of 4036 Ovarian Cancer Patients According to the 2013 FIGO Classification for Ovarian, Fallopian Tube, and Primary Peritoneal Cancer","volume":"26","author":"Rosendahl","year":"2016","journal-title":"Int. J. Gynecol. Cancer"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1093\/jnci\/djy071","article-title":"Invasive Epithelial Ovarian Cancer Survival by Histotype and Disease Stage","volume":"111","author":"Peres","year":"2019","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"284","DOI":"10.3322\/caac.21456","article-title":"Ovarian Cancer Statistics, 2018","volume":"68","author":"Torre","year":"2018","journal-title":"CA Cancer J. Clin."},{"key":"ref_12","unstructured":"(2022, June 22). SEER Cancer Statistics Review, 1975\u20132014, Available online: https:\/\/seer.cancer.gov\/archive\/csr\/1975_2014\/#contents."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ijgo.2013.10.001","article-title":"Staging Classification for Cancer of the Ovary, Fallopian Tube, and Peritoneum","volume":"124","author":"Prat","year":"2014","journal-title":"Int. J. Gynaecol.Obstet."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1007\/s00404-014-3364-8","article-title":"The New FIGO Staging System for Ovarian, Fallopian Tube, and Primary Peritoneal Cancer","volume":"290","author":"Zeppernick","year":"2014","journal-title":"Arch. Gynecol. Obstet."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"53","DOI":"10.3892\/ijo.2021.5233","article-title":"A Multidisciplinary Approach Remains the Best Strategy to Improve and Strengthen the Management of Ovarian Cancer","volume":"59","author":"Falzone","year":"2021","journal-title":"Int. J. Oncol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"541842","DOI":"10.1155\/2012\/541842","article-title":"Diagnosis and Management of Peritoneal Metastases from Ovarian Cancer","volume":"2012","author":"Halkia","year":"2012","journal-title":"Gastroenterol. Res. Pract."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"S161","DOI":"10.1016\/S0020-7292(06)60033-7","article-title":"Carcinoma of the Ovary. FIGO 26th Annual Report on the Results of Treatment in Gynecological Cancer","volume":"95","author":"Heintz","year":"2006","journal-title":"Int. J. Gynaecol. Obstet."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"3253","DOI":"10.21873\/anticanres.15111","article-title":"Multimodal Treatment of Primary Advanced Ovarian Cancer","volume":"41","author":"Friedrich","year":"2021","journal-title":"Anticancer Res."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1002\/cncr.24149","article-title":"Role of Surgical Outcome as Prognostic Factor in Advanced Epithelial Ovarian Cancer: A Combined Exploratory Analysis of 3 Prospectively Randomized Phase 3 Multicenter Trials: By the Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR) and the Groupe d\u2019Investigateurs Nationaux Pour Les Etudes Des Cancers de l\u2019Ovaire (GINECO)","volume":"115","author":"Reuss","year":"2009","journal-title":"Cancer"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.critrevonc.2015.03.007","article-title":"Hyperthermic Intraperitoneal Chemotherapy for the Treatment of Ovarian Cancer: A Brief Overview of Recent Results","volume":"95","author":"Roviello","year":"2015","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1002\/ijgo.13878","article-title":"Cancer of the Ovary, Fallopian Tube, and Peritoneum: 2021 Update","volume":"155","author":"Berek","year":"2021","journal-title":"Int. J. Gynaecol. Obstet."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"x16","DOI":"10.1093\/annonc\/mdt463","article-title":"Origin and Molecular Pathogenesis of Ovarian High-Grade Serous Carcinoma","volume":"24","author":"Kurman","year":"2013","journal-title":"Ann. Oncol. Off. J. Eur. Soc. Med. Oncol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1016\/j.ajpath.2015.11.011","article-title":"The Dualistic Model of Ovarian Carcinogenesis: Revisited, Revised, and Expanded","volume":"186","author":"Kurman","year":"2016","journal-title":"Am. J. Pathol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1016\/j.humpath.2011.03.003","article-title":"Molecular Pathogenesis and Extraovarian Origin of Epithelial Ovarian Cancer\u2014Shifting the Paradigm","volume":"42","author":"Kurman","year":"2011","journal-title":"Hum. Pathol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1634\/theoncologist.2015-0239","article-title":"Advanced Ovarian Cancer: Primary or Interval Debulking? Five Categories of Patients in View of the Results of Randomized Trials and Tumor Biology: Primary Debulking Surgery and Interval Debulking Surgery for Advanced Ovarian Cancer","volume":"21","author":"Makar","year":"2016","journal-title":"Oncologist"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1818","DOI":"10.1038\/bjc.2011.455","article-title":"Role of Histological Type on Surgical Outcome and Survival Following Radical Primary Tumour Debulking of Epithelial Ovarian, Fallopian Tube and Peritoneal Cancers","volume":"105","author":"Braicu","year":"2011","journal-title":"Br. J. Cancer"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1055\/s-0035-1558079","article-title":"Statement by the Kommission Ovar of the AGO: The New FIGO and WHO Classifications of Ovarian, Fallopian Tube and Primary Peritoneal Cancer","volume":"75","author":"Fotopoulou","year":"2015","journal-title":"Geburtshilfe Frauenheilkd."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1159\/000479006","article-title":"Ovarian Cancer: A Heterogeneous Disease","volume":"85","author":"Leary","year":"2018","journal-title":"Pathobiology"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1007\/s00404-016-4035-8","article-title":"The New WHO Classification of Ovarian, Fallopian Tube, and Primary Peritoneal Cancer and Its Clinical Implications","volume":"293","author":"Fotopoulou","year":"2016","journal-title":"Arch. Gynecol. Obstet."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"viii8","DOI":"10.1093\/annonc\/mdx445","article-title":"The New Classifications of Ovarian, Fallopian Tube, and Primary Peritoneal Cancer and Their Clinical Implications","volume":"28","author":"Duska","year":"2017","journal-title":"Ann. Oncol. Off. J. Eur. Soc. Med. Oncol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1038\/nrg3317","article-title":"Evolution of the Cancer Genome","volume":"13","author":"Yates","year":"2012","journal-title":"Nat. Rev. Genet."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1038\/nrc2627","article-title":"Parallel Progression of Primary Tumours and Metastases","volume":"9","author":"Klein","year":"2009","journal-title":"Nat. Rev. Cancer"},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Schwarz, R.F., Ng, C.K.Y., Cooke, S.L., Newman, S., Temple, J., Piskorz, A.M., Gale, D., Sayal, K., Murtaza, M., and Baldwin, P.J. (2015). Spatial and Temporal Heterogeneity in High-Grade Serous Ovarian Cancer: A Phylogenetic Analysis. PLoS Med., 12.","DOI":"10.1371\/journal.pmed.1001789"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"58","DOI":"10.3892\/ijo.2022.5349","article-title":"Identification of the Most Common BRCA Alterations through Analysis of Germline Mutation Databases: Is Droplet Digital PCR an Additional Strategy for the Assessment of Such Alterations in Breast and Ovarian Cancer Families?","volume":"60","author":"Lavoro","year":"2022","journal-title":"Int. J. Oncol."},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Cancer Genome Atlas Research Network (2011). Integrated Genomic Analyses of Ovarian Carcinoma. Nature, 474, 609\u2013615.","DOI":"10.1038\/nature10166"},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Lee, Y.J., Kim, H.-S., Rim, J.H., Lee, J.-Y., Nam, E.J., Kim, S.W., Kim, S., and Kim, Y.T. (2020). Germline BRCA, Chemotherapy Response Scores, and Survival in the Neoadjuvant Treatment of Ovarian Cancer. BMC Cancer, 20.","DOI":"10.1186\/s12885-020-6688-8"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"73","DOI":"10.5152\/jtgga.2016.15223","article-title":"Primary Peritoneal Cancer in BRCA Carriers after Prophylactic Bilateral Salpingo-Oophorectomy","volume":"17","author":"Iavazzo","year":"2016","journal-title":"J. Turkish Ger. Gynecol. Assoc."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"5289","DOI":"10.1007\/s12325-022-02259-2","article-title":"Recurrent Ovarian Cancer with BRCAness Phenotype: A Treatment Challenge","volume":"39","author":"Caeiro","year":"2022","journal-title":"Adv. Ther."},{"key":"ref_39","doi-asserted-by":"crossref","unstructured":"Madariaga, A., Lheureux, S., and Oza, A. (2019). Tailoring Ovarian Cancer Treatment: Implications of BRCA1\/2 Mutations. Cancers, 11.","DOI":"10.3390\/cancers11030416"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1002\/gcc.22935","article-title":"PARP Inhibitors in Ovarian Cancer: An Overview of the Practice-changing Trials","volume":"60","author":"Foo","year":"2021","journal-title":"Genes Chromosom. Cancer"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"225","DOI":"10.2217\/fon-2019-0042","article-title":"Bevacizumab Use in the Frontline, Maintenance and Recurrent Settings for Ovarian Cancer","volume":"16","author":"Haunschild","year":"2020","journal-title":"Futur. Oncol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1177\/0300891620966382","article-title":"Management of Ovarian Cancer: Guidelines of the Italian Medical Oncology Association (AIOM)","volume":"107","author":"Gadducci","year":"2021","journal-title":"Tumori"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1007\/s11605-020-04771-8","article-title":"The Role of Hyperthermic Intraperitoneal Chemotherapy for Non-Colorectal Peritoneal Surface Malignancies","volume":"25","author":"Morris","year":"2021","journal-title":"J. Gastrointest. Surg."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"2553","DOI":"10.1002\/cncr.32867","article-title":"The Chicago Consensus on Peritoneal Surface Malignancies: Management of Ovarian Neoplasms","volume":"126","author":"Hoppenot","year":"2020","journal-title":"Cancer"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.ygyno.2009.12.033","article-title":"Quality of Care in Advanced Ovarian Cancer: The Importance of Provider Specialty","volume":"117","author":"Mercado","year":"2010","journal-title":"Gynecol. Oncol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1038\/s41572-021-00326-6","article-title":"Primary and Metastatic Peritoneal Surface Malignancies","volume":"7","author":"Alyami","year":"2021","journal-title":"Nat. Rev. Dis. Prim."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1002\/(SICI)1097-0142(20000115)88:2<358::AID-CNCR16>3.0.CO;2-O","article-title":"Peritoneal Carcinomatosis from Non-Gynecologic Malignancies: Results of the EVOCAPE 1 Multicentric Prospective Study","volume":"88","author":"Sadeghi","year":"2000","journal-title":"Cancer"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.suronc.2010.12.001","article-title":"Peritoneal Surface Malignancies and Regional Treatment: A Review of the Literature","volume":"21","author":"Rubino","year":"2012","journal-title":"Surg. Oncol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1097\/00000658-199501000-00004","article-title":"Peritonectomy Procedures","volume":"221","author":"Sugarbaker","year":"1995","journal-title":"Ann. Surg."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1007\/s004230050246","article-title":"Management of Peritoneal-Surface Malignancy: The Surgeon\u2019s Role","volume":"384","author":"Sugarbaker","year":"1999","journal-title":"Langenbecks Arch. Surg."},{"key":"ref_51","first-page":"256","article-title":"Clinical Delivery System for Intraperitoneal Hyperthermic Chemotherapy","volume":"40","author":"Spratt","year":"1980","journal-title":"Cancer Res."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"e368","DOI":"10.1016\/S1470-2045(19)30318-3","article-title":"Pressurised Intraperitoneal Aerosol Chemotherapy: Rationale, Evidence, and Potential Indications","volume":"20","author":"Alyami","year":"2019","journal-title":"Lancet Oncol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"2370","DOI":"10.1245\/s10434-010-1039-7","article-title":"Peritoneal Carcinomatosis from Gastric Cancer: A Multi-Institutional Study of 159 Patients Treated by Cytoreductive Surgery Combined with Perioperative Intraperitoneal Chemotherapy","volume":"17","author":"Glehen","year":"2010","journal-title":"Ann. Surg. Oncol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1515\/pp-2017-0003","article-title":"Overview of the Optimal Perioperative Intraperitoneal Chemotherapy Regimens Used in Current Clinical Practice","volume":"2","author":"Lemoine","year":"2017","journal-title":"Pleura Peritoneum"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.ejca.2019.10.034","article-title":"Indications for Hyperthermic Intraperitoneal Chemotherapy with Cytoreductive Surgery: A Systematic Review","volume":"127","author":"Auer","year":"2020","journal-title":"Eur. J. Cancer"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"896","DOI":"10.6004\/jnccn.2019.0039","article-title":"NCCN Guidelines Insights: Ovarian Cancer, Version 1.2019","volume":"17","author":"Armstrong","year":"2019","journal-title":"J. Natl. Compr. Cancer Netw."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1177\/1758834014544891","article-title":"Neoadjuvant Chemotherapy in Advanced Ovarian Cancer: Latest Results and Place in Therapy","volume":"6","author":"Sato","year":"2014","journal-title":"Ther. Adv. Med. Oncol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"100737","DOI":"10.1016\/j.currproblcancer.2021.100737","article-title":"Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in the Management of Peritoneal Surface Malignancies\u2014An Evidence-Based Review","volume":"45","author":"Ray","year":"2021","journal-title":"Curr. Probl. Cancer"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1002\/ijgo.13542","article-title":"The Impacts of Neoadjuvant Chemotherapy and of Cytoreductive Surgery on 10-Year Survival from Advanced Ovarian Cancer","volume":"153","author":"Kim","year":"2021","journal-title":"Int. J. Gynaecol. Obstet."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1093\/jjco\/hyaa015","article-title":"Clinical Significance of Primary Debulking Surgery and Neoadjuvant Chemotherapy-Interval Debulking Surgery in Advanced Ovarian Cancer","volume":"50","author":"Nishio","year":"2020","journal-title":"Jpn. J. Clin. Oncol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1038\/nrclinonc.2015.26","article-title":"A Framework for a Personalized Surgical Approach to Ovarian Cancer","volume":"12","author":"Nick","year":"2015","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.6004\/jnccn.2012.0140","article-title":"Ovarian Cancer, Version 3.2012","volume":"10","author":"Morgan","year":"2012","journal-title":"J. Natl. Compr. Cancer Netw."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/s10147-018-1319-y","article-title":"Bevacizumab Combined with Platinum-Taxane Chemotherapy as First-Line Treatment for Advanced Ovarian Cancer: A Prospective Observational Study of Safety and Efficacy in Japanese Patients (JGOG3022 Trial)","volume":"24","author":"Komiyama","year":"2019","journal-title":"Int. J. Clin. Oncol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1093\/annonc\/mdx011","article-title":"Fifth Ovarian Cancer Consensus Conference of the Gynecologic Cancer InterGroup: First-Line Interventions","volume":"28","author":"Karam","year":"2017","journal-title":"Ann. Oncol. Off. J. Eur. Soc. Med. Oncol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/S1470-2045(14)71135-0","article-title":"Olaparib Combined with Chemotherapy for Recurrent Platinum-Sensitive Ovarian Cancer: A Randomised Phase 2 Trial","volume":"16","author":"Oza","year":"2015","journal-title":"Lancet Oncol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1200\/JCO.2013.51.4489","article-title":"Bevacizumab Combined with Chemotherapy for Platinum-Resistant Recurrent Ovarian Cancer: The AURELIA Open-Label Randomized Phase III Trial","volume":"32","author":"Hilpert","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"2484","DOI":"10.1056\/NEJMoa1103799","article-title":"A Phase 3 Trial of Bevacizumab in Ovarian Cancer","volume":"365","author":"Perren","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.2147\/OTT.S155425","article-title":"First-Line Treatment of Women with Advanced Ovarian Cancer: Focus on Bevacizumab","volume":"12","author":"Marchetti","year":"2019","journal-title":"Onco-Targets Ther."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1016\/j.ygyno.2014.07.004","article-title":"The Impacts of Neoadjuvant Chemotherapy and of Debulking Surgery on Survival from Advanced Ovarian Cancer","volume":"134","author":"Rosen","year":"2014","journal-title":"Gynecol. Oncol."},{"key":"ref_70","doi-asserted-by":"crossref","unstructured":"Cummings, M., Nicolais, O., and Shahin, M. (2022). Surgery in Advanced Ovary Cancer: Primary versus Interval Cytoreduction. Diagnostics, 12.","DOI":"10.3390\/diagnostics12040988"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1056\/NEJMoa0908806","article-title":"Neoadjuvant Chemotherapy or Primary Surgery in Stage IIIC or IV Ovarian Cancer","volume":"363","author":"Vergote","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/S0140-6736(14)62223-6","article-title":"Primary Chemotherapy versus Primary Surgery for Newly Diagnosed Advanced Ovarian Cancer (CHORUS): An Open-Label, Randomised, Controlled, Non-Inferiority Trial","volume":"386","author":"Kehoe","year":"2015","journal-title":"Lancet"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.ygyno.2011.08.014","article-title":"An Analysis of Patients with Bulky Advanced Stage Ovarian, Tubal, and Peritoneal Carcinoma Treated with Primary Debulking Surgery (PDS) during an Identical Time Period as the Randomized EORTC-NCIC Trial of PDS vs Neoadjuvant Chemotherapy (NACT)","volume":"124","author":"Chi","year":"2012","journal-title":"Gynecol. Oncol."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.ejca.2020.02.020","article-title":"Comparison of Survival between Primary Debulking Surgery and Neoadjuvant Chemotherapy for Stage III\/IV Ovarian, Tubal and Peritoneal Cancers in Phase III Randomised Trial","volume":"130","author":"Onda","year":"2020","journal-title":"Eur. J. Cancer"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1136\/ijgc-2020-001640","article-title":"Randomized Trial of Primary Debulking Surgery versus Neoadjuvant Chemotherapy for Advanced Epithelial Ovarian Cancer (SCORPION-NCT01461850)","volume":"30","author":"Fagotti","year":"2020","journal-title":"Int. J. Gynecol. Cancer"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"e86","DOI":"10.3802\/jgo.2020.31.e86","article-title":"Study of Upfront Surgery versus Neoadjuvant Chemotherapy Followed by Interval Debulking Surgery for Patients with Stage Iiic and Iv Ovarian Cancer, Sgog Sunny (SOC-2) Trial Concept","volume":"31","author":"Jiang","year":"2020","journal-title":"J. Gynecol. Oncol."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1136\/ijgc-2019-000682","article-title":"TRUST: Trial of Radical Upfront Surgical Therapy in Advanced Ovarian Cancer (ENGOT Ov33\/AGO-OVAR OP7)","volume":"29","author":"Reuss","year":"2019","journal-title":"Int. J. Gynecol. Cancer"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1136\/ijgc-2021-003320","article-title":"CHRONO: Randomized Trial of the CHROnology of Surgery after Neoadjuvant Chemotherapy for Ovarian Cancer","volume":"32","author":"Classe","year":"2022","journal-title":"Int. J. Gynecol. Cancer"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"2435","DOI":"10.1016\/S0959-8049(02)00495-1","article-title":"Moderate Progress for Ovarian Cancer in the Last 20 Years: Prolongation of Survival, but No Improvement in the Cure Rate","volume":"38","author":"Engel","year":"2002","journal-title":"Eur. J. Cancer"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"2138","DOI":"10.1200\/JCO.21.02011","article-title":"Olaparib with or without Cediranib versus Platinum-Based Chemotherapy in Recurrent Platinum-Sensitive Ovarian Cancer (NRG-GY004): A Randomized, Open-Label, Phase III Trial","volume":"40","author":"Liu","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1136\/ijgc-2021-003116","article-title":"BRCA Status and Platinum Sensitivity in Advanced Ovarian Cancer According to Chemotherapy Response Score","volume":"32","author":"Ergasti","year":"2022","journal-title":"Int. J. Gynecol. Cancer"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"5256","DOI":"10.1002\/cncr.33167","article-title":"Hyperthermic Intraperitoneal Chemotherapy in Interval Debulking Surgery for Advanced Epithelial Ovarian Cancer: A Single-Center, Real-Life Experience","volume":"126","author":"Ghirardi","year":"2020","journal-title":"Cancer"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1056\/NEJM199503093321002","article-title":"The Effect of Debulking Surgery after Induction Chemotherapy on the Prognosis in Advanced Epithelial Ovarian Cancer. Gynecological Cancer Cooperative Group of the European Organization for Research and Treatment of Cancer","volume":"332","author":"Buyse","year":"1995","journal-title":"N. Engl. J. Med."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.ygyno.2018.08.014","article-title":"Continuous Improvement in Primary Debulking Surgery for Advanced Ovarian Cancer: Do Increased Complete Gross Resection Rates Independently Lead to Increased Progression-Free and Overall Survival?","volume":"151","author":"Tseng","year":"2018","journal-title":"Gynecol. Oncol."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1200\/JCO.2014.56.3106","article-title":"Does Aggressive Surgery Improve Outcomes? Interaction between Preoperative Disease Burden and Complex Surgery in Patients with Advanced-Stage Ovarian Cancer: An Analysis of GOG 182","volume":"33","author":"Horowitz","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/j.ygyno.2013.05.040","article-title":"Survival Impact of Complete Cytoreduction to No Gross Residual Disease for Advanced-Stage Ovarian Cancer: A Meta-Analysis","volume":"130","author":"Chang","year":"2013","journal-title":"Gynecol. Oncol."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"dju048","DOI":"10.1093\/jnci\/dju048","article-title":"Risk Prediction for Late-Stage Ovarian Cancer by Meta-Analysis of 1525 Patient Samples","volume":"106","author":"Riester","year":"2014","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"4077","DOI":"10.1158\/1078-0432.CCR-17-0246","article-title":"Pooled Clustering of High-Grade Serous Ovarian Cancer Gene Expression Leads to Novel Consensus Subtypes Associated with Survival and Surgical Outcomes","volume":"23","author":"Wang","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"ref_89","doi-asserted-by":"crossref","unstructured":"Boccardi, V., Marano, L., Rossetti, R.R.A., Rizzo, M.R., Di Martino, N., and Paolisso, G. (2015). Serum CD26 Levels in Patients with Gastric Cancer: A Novel Potential Diagnostic Marker. BMC Cancer, 15.","DOI":"10.1186\/s12885-015-1757-0"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1056\/NEJMoa1808424","article-title":"A Randomized Trial of Lymphadenectomy in Patients with Advanced Ovarian Neoplasms","volume":"380","author":"Harter","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_91","first-page":"5500","article-title":"LION: Lymphadenectomy in Ovarian Neoplasms\u2014A Prospective Randomized AGO Study Group Led Gynecologic Cancer Intergroup Trial","volume":"35","author":"Harter","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.ejso.2019.02.031","article-title":"A Comparison of Outcomes Following Total and Selective Peritonectomy Performed at the Time of Interval Cytoreductive Surgery for Advanced Serous Epithelial Ovarian, Fallopian Tube and Primary Peritoneal Cancer\u2014A Study by INDEPSO","volume":"47","author":"Sinukumar","year":"2021","journal-title":"Eur. J. Surg. Oncol."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1016\/S1470-2045(14)70049-X","article-title":"Carboplatin plus Paclitaxel Once a Week versus Every 3 Weeks in Patients with Advanced Ovarian Cancer (MITO-7): A Randomised, Multicentre, Open-Label, Phase 3 Trial","volume":"15","author":"Pignata","year":"2014","journal-title":"Lancet Oncol."},{"key":"ref_94","doi-asserted-by":"crossref","unstructured":"Clamp, A.R., James, E.C., McNeish, I.A., Dean, A., Kim, J.-W., O\u2019Donnell, D.M., Gallardo-Rincon, D., Blagden, S., Brenton, J., and Perren, T.J. (2022). Weekly Dose-Dense Chemotherapy in First-Line Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Treatment (ICON8): Overall Survival Results from an Open-Label, Randomised, Controlled, Phase 3 Trial. Lancet Oncol.","DOI":"10.1016\/S1470-2045(22)00283-2"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1016\/S0140-6736(09)61157-0","article-title":"Dose-Dense Paclitaxel Once a Week in Combination with Carboplatin Every 3 Weeks for Advanced Ovarian Cancer: A Phase 3, Open-Label, Randomised Controlled Trial","volume":"374","author":"Katsumata","year":"2009","journal-title":"Lancet"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1093\/annonc\/mdv500","article-title":"Early Initiation of Chemotherapy Following Complete Resection of Advanced Ovarian Cancer Associated with Improved Survival: NRG Oncology\/Gynecologic Oncology Group Study","volume":"27","author":"Tewari","year":"2016","journal-title":"Ann. Oncol. Off. J. Eur. Soc. Med. Oncol."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1016\/j.hoc.2018.07.010","article-title":"Diagnosis and Treatment of Ovarian Cancer","volume":"32","author":"Orr","year":"2018","journal-title":"Hematol. Oncol. Clin. N. Am."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.ygyno.2013.07.086","article-title":"The Time Interval from Surgery to Start of Chemotherapy Significantly Impacts Prognosis in Patients with Advanced Serous Ovarian Carcinoma\u2014Analysis of Patient Data in the Prospective OVCAD Study","volume":"131","author":"Hofstetter","year":"2013","journal-title":"Gynecol. Oncol."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1016\/S0140-6736(13)62146-7","article-title":"Ovarian Cancer","volume":"384","author":"Jayson","year":"2014","journal-title":"Lancet"},{"key":"ref_100","first-page":"CD005343","article-title":"Chemotherapy versus Surgery for Initial Treatment in Advanced Ovarian Epithelial Cancer","volume":"2019","author":"Coleridge","year":"2019","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1038\/nrclinonc.2015.224","article-title":"Can Advanced-Stage Ovarian Cancer Be Cured?","volume":"13","author":"Narod","year":"2016","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1097\/AOG.0000000000000981","article-title":"Characteristics of Long-Term Survivors of Epithelial Ovarian Cancer","volume":"126","author":"Cress","year":"2015","journal-title":"Obstet. Gynecol."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1097\/00000658-189407000-00075","article-title":"The Results of Operations for the Cure of Cancer of the Breast Performed at the Johns Hopkins Hospital from June, 1889, to January, 1894","volume":"20","author":"Halsted","year":"1894","journal-title":"Ann. Surg."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"e93","DOI":"10.3802\/jgo.2019.30.e93","article-title":"Evaluation of Non-Completion of Intraperitoneal Chemotherapy in Patients with Advanced Epithelial Ovarian Cancer","volume":"30","author":"Chambers","year":"2019","journal-title":"J. Gynecol. Oncol."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"484","DOI":"10.5468\/ogs.2014.57.6.484","article-title":"Survival Outcomes and Toxicity of Intraoperative Intraperitoneal Chemotherapy in Advanced Epithelial Ovarian Cancer","volume":"57","author":"Yoon","year":"2014","journal-title":"Obstet. Gynecol. Sci."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1200\/JCO.2014.55.9898","article-title":"Long-Term Survival Advantage and Prognostic Factors Associated with Intraperitoneal Chemotherapy Treatment in Advanced Ovarian Cancer: A Gynecologic Oncology Group Study","volume":"33","author":"Tewari","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"ref_107","doi-asserted-by":"crossref","unstructured":"Mazurek, M., Szlendak, M., Forma, A., Baj, J., Maciejewski, R., Roviello, G., Marano, L., Roviello, F., Polom, K., and Sitarz, R. (2022). Hyperthermic Intraperitoneal Chemotherapy in the Management of Gastric Cancer: A Narrative Review. Int. J. Environ. Res. Public Health, 19.","DOI":"10.3390\/ijerph19020681"},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"9060","DOI":"10.1245\/s10434-021-10157-0","article-title":"Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Gastric Cancer with Synchronous Peritoneal Metastases: Multicenter Study of \u201cItalian Peritoneal Surface Malignancies Oncoteam-S.I.C.O.\u201d","volume":"28","author":"Marano","year":"2021","journal-title":"Ann. Surg. Oncol."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"19","DOI":"10.4251\/wjgo.v2.i1.19","article-title":"Pharmacologic Rationale for Treatments of Peritoneal Surface Malignancy from Colorectal Cancer","volume":"2","author":"Sugarbaker","year":"2010","journal-title":"World J. Gastrointest. Oncol."},{"key":"ref_110","doi-asserted-by":"crossref","unstructured":"Riggs, M.J., Pandalai, P.K., Kim, J., and Dietrich, C.S. (2020). Hyperthermic Intraperitoneal Chemotherapy in Ovarian Cancer. Diagnostics, 10.","DOI":"10.3390\/diagnostics10010043"},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"44","DOI":"10.21037\/cco-20-49","article-title":"Role of Hyperthermic Intraperitoneal Chemotherapy in Ovarian Cancer","volume":"9","year":"2020","journal-title":"Chin. Clin. Oncol."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"68","DOI":"10.4251\/wjgo.v2.i2.68","article-title":"Hyperthermic Intraperitoneal Chemotherapy: Rationale and Technique","volume":"2","year":"2010","journal-title":"World J. Gastrointest. Oncol."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1002\/jso.21682","article-title":"Safety and Potential Benefit of Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Peritoneal Carcinomatosis from Primary or Recurrent Ovarian Cancer","volume":"102","author":"Roviello","year":"2010","journal-title":"J. Surg. Oncol."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1002\/jso.24666","article-title":"Hyperthermic Intraperitoneal Chemoperfusion as a Component of Multimodality Therapy for Ovarian and Primary Peritoneal Cancer","volume":"116","author":"Magge","year":"2017","journal-title":"J. Surg. Oncol."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.ejso.2015.11.006","article-title":"Peritonectomy Procedures and HIPEC in the Treatment of Peritoneal Carcinomatosis from Ovarian Cancer: Long-Term Outcomes and Perspectives from a High-Volume Center","volume":"42","author":"Rubio","year":"2016","journal-title":"Eur. J. Surg. Oncol."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1186\/s13048-019-0509-1","article-title":"The Prognosis Impact of Hyperthermic Intraperitoneal Chemotherapy (HIPEC) plus Cytoreductive Surgery (CRS) in Advanced Ovarian Cancer: The Meta-Analysis","volume":"12","author":"Zhang","year":"2019","journal-title":"J. Ovarian Res."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"298","DOI":"10.3109\/02656736.2016.1149233","article-title":"Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Treatment of Ovarian Cancer","volume":"32","author":"Polom","year":"2016","journal-title":"Int. J. Hyperthermia"},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1016\/j.ejso.2015.08.172","article-title":"Hyperthermic Intraperitoneal Chemotherapy (HIPEC) and Cytoreductive Surgery (CRS) in Ovarian Cancer: A Systematic Review and Meta-Analysis","volume":"41","author":"Huo","year":"2015","journal-title":"Eur. J. Surg. Oncol."},{"key":"ref_119","first-page":"CD005340","article-title":"Intraperitoneal Chemotherapy for the Initial Management of Primary Epithelial Ovarian Cancer","volume":"2016","author":"Jaaback","year":"2016","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1097\/00000421-198212000-00014","article-title":"Toxicity and Response Criteria of the Eastern Cooperative Oncology Group","volume":"5","author":"Oken","year":"1982","journal-title":"Am. J. Clin. Oncol."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"S137","DOI":"10.21037\/jgo-20-274","article-title":"Narrative Review of Cytoreductive Surgery and Intraperitoneal Chemotherapy for Peritoneal Metastases in Ovarian Cancer","volume":"12","author":"Boerner","year":"2021","journal-title":"J. Gastrointest. Oncol."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"e2013940","DOI":"10.1001\/jamanetworkopen.2020.13940","article-title":"Evaluation of Cytoreductive Surgery with or without Hyperthermic Intraperitoneal Chemotherapy for Stage III Epithelial Ovarian Cancer","volume":"3","author":"Lei","year":"2020","journal-title":"JAMA Netw. Open"},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"2617","DOI":"10.1245\/s10434-021-11087-7","article-title":"Cytoreductive Surgery with or without HIPEC after Neoadjuvant Chemotherapy in Ovarian Cancer: A Phase 3 Clinical Trial","volume":"29","author":"Antonio","year":"2022","journal-title":"Ann. Surg. Oncol."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1016\/j.ejso.2013.09.030","article-title":"Peritoneal Carcinomatosis Treated with Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for Advanced Ovarian Carcinoma: A French Multicentre Retrospective Cohort Study of 566 Patients","volume":"39","author":"Bakrin","year":"2013","journal-title":"Eur. J. Surg. Oncol."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"3194","DOI":"10.1200\/JCO.2003.02.153","article-title":"Phase III Trial of Carboplatin and Paclitaxel Compared with Cisplatin and Paclitaxel in Patients with Optimally Resected Stage III Ovarian Cancer: A Gynecologic Oncology Group Study","volume":"21","author":"Ozols","year":"2003","journal-title":"J. Clin. Oncol."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1056\/NEJM199601043340101","article-title":"Cyclophosphamide and Cisplatin Compared with Paclitaxel and Cisplatin in Patients with Stage III and Stage IV Ovarian Cancer","volume":"334","author":"McGuire","year":"1996","journal-title":"N. Engl. J. Med."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"e38","DOI":"10.1016\/j.suronc.2010.09.002","article-title":"Treatment of Peritoneal Carcinomatosis with Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy: State of the Art and Future Developments","volume":"20","author":"Roviello","year":"2011","journal-title":"Surg. Oncol."},{"key":"ref_128","first-page":"54","article-title":"Cytoreductive Surgery Using Peritonectomy and Visceral Resections for Peritoneal Surface Malignancy","volume":"2","author":"Sugarbaker","year":"2013","journal-title":"Transl. Gastrointest. Cancer"},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1097\/IGC.0000000000001132","article-title":"National Trends in Extended Procedures for Ovarian Cancer Debulking Surgery","volume":"28","author":"Jones","year":"2018","journal-title":"Int. J. Gynecol. Cancer"},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1111\/IGC.0b013e3181c50cde","article-title":"Hyperthermic Intraperitoneal Chemotherapy in Ovarian Cancer: First Report of the HYPER-O Registry","volume":"20","author":"Helm","year":"2010","journal-title":"Int. J. Gynecol. Cancer"},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"e20223135","DOI":"10.1590\/0100-6991e-20223135","article-title":"A Phase 2 Trial of Short-Course Hyperthermic IntraPeritoneal Chemotherapy (HIPEC) at Interval Cytoreductive Surgery (ICRS) for Advanced Ovarian Cancer","volume":"49","author":"Batista","year":"2022","journal-title":"Rev. Col. Bras. Cir."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"869","DOI":"10.2147\/CMAR.S153327","article-title":"Neoadjuvant Chemotherapy Followed by Fast-Track Cytoreductive Surgery plus Short-Course Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Advanced Ovarian Cancer: Preliminary Results of a Promising All-in-One Approach","volume":"9","author":"Batista","year":"2017","journal-title":"Cancer Manag. Res."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1200\/JCO.2001.19.4.1001","article-title":"Phase III Trial of Standard-Dose Intravenous Cisplatin plus Paclitaxel versus Moderately High-Dose Carboplatin Followed by Intravenous Paclitaxel and Intraperitoneal Cisplatin in Small-Volume Stage III Ovarian Carcinoma: An Intergroup Study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern Cooperative Oncology Group","volume":"19","author":"Markman","year":"2001","journal-title":"J. Clin. Oncol."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1093\/jjco\/hyq182","article-title":"A Randomized Phase II\/III Trial of 3 Weekly Intraperitoneal versus Intravenous Carboplatin in Combination with Intravenous Weekly Dose-Dense Paclitaxel for Newly Diagnosed Ovarian, Fallopian Tube and Primary Peritoneal Cancer","volume":"41","author":"Fujiwara","year":"2011","journal-title":"Jpn. J. Clin. Oncol."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"e3","DOI":"10.3802\/jgo.2019.30.e3","article-title":"Incorporation of Paclitaxel-Based Hyperthermic Intraperitoneal Chemotherapy in Patients with Advanced-Stage Ovarian Cancer Treated with Neoadjuvant Chemotherapy Followed by Interval Debulking Surgery: A Protocol-Based Pilot Study","volume":"30","author":"Lee","year":"2019","journal-title":"J. Gynecol. Oncol."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1007\/s12094-019-02065-3","article-title":"The Use of Cisplatin plus Doxorubicin or Paclitaxel in Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for Stage IIIC or IV Epithelial Ovarian Cancer: A Comparative Study","volume":"21","author":"Manzanedo","year":"2019","journal-title":"Clin. Transl. Oncol."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"S144","DOI":"10.21037\/jgo-2020-06","article-title":"Intraperitoneal Chemotherapy for Ovarian Cancer with Peritoneal Metastases, Systematic Review of the Literature and Focused Personal Experience","volume":"12","author":"Coccolini","year":"2021","journal-title":"J. Gastrointest. Oncol."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1200\/JCO.18.01568","article-title":"Randomized Trial of Intravenous versus Intraperitoneal Chemotherapy Plus Bevacizumab in Advanced Ovarian Carcinoma: An NRG Oncology\/Gynecologic Oncology Group Study","volume":"37","author":"Walker","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"100149","DOI":"10.1016\/j.esmoop.2021.100149","article-title":"Role of Surgery and Hyperthermic Intraperitoneal Chemotherapy in Ovarian Cancer","volume":"6","author":"Kim","year":"2021","journal-title":"ESMO Open"},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1056\/NEJMoa1708618","article-title":"Hyperthermic Intraperitoneal Chemotherapy in Ovarian Cancer","volume":"378","author":"Koole","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1001\/jamasurg.2022.0143","article-title":"Survival after Hyperthermic Intraperitoneal Chemotherapy and Primary or Interval Cytoreductive Surgery in Ovarian Cancer","volume":"157","author":"Lim","year":"2022","journal-title":"JAMA Surg."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"101523","DOI":"10.1016\/j.suronc.2021.101523","article-title":"A Novel Treatment Protocol with 6 Cycles of Neoadjuvant Chemotherapy Followed by Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Stage III Primary Ovarian Cancer","volume":"37","author":"Marrelli","year":"2021","journal-title":"Surg. Oncol."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.ejogrb.2019.04.007","article-title":"RECIST 1.1 Criteria Predict Recurrence-Free Survival in Advanced Ovarian Cancer Submitted to Neoadjuvant Chemotherapy","volume":"237","author":"Bogani","year":"2019","journal-title":"Eur. J. Obstet. Gynecol. Reprod. Biol."},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1136\/ijgc-2020-001231","article-title":"Primary Cytoreductive Surgery with or without Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for FIGO Stage III Epithelial Ovarian Cancer: OVHIPEC-2, a Phase III Randomized Clinical Trial","volume":"30","author":"Koole","year":"2020","journal-title":"Int. J. Gynecol. Cancer"},{"key":"ref_145","unstructured":"Cui, S., and Lin, Z. (2017, December 14). Efficacy of HIPEC in the Treatment of Advanced-Stage Epithelial Ovarian Cancer after Cytoreductive Surgery, Available online: ClinicalTrials.Gov."},{"key":"ref_146","doi-asserted-by":"crossref","unstructured":"Jewell, A., Mcmahon, M., and Khabele, D. (2018). Cancers Heated Intraperitoneal Chemotherapy in the Management of Advanced Ovarian Cancer. Cancers, 10.","DOI":"10.20944\/preprints201806.0088.v1"},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"2383","DOI":"10.1245\/s10434-014-3599-4","article-title":"Treatment of Microscopic Disease with Hyperthermic Intraoperative Intraperitoneal Chemotherapy after Complete Cytoreduction Improves Disease-Free Survival in Patients with Stage IIIC\/IV Ovarian Cancer","volume":"21","author":"Gil","year":"2014","journal-title":"Ann. Surg. Oncol."},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1038\/bjc.2013.70","article-title":"BRCA1 Expression and Improved Survival in Ovarian Cancer Patients Treated with Intraperitoneal Cisplatin and Paclitaxel: A Gynecologic Oncology Group Study","volume":"108","author":"Lesnock","year":"2013","journal-title":"Br. J. Cancer"},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1093\/annonc\/mdx010","article-title":"Fifth Ovarian Cancer Consensus Conference: Individualized Therapy and Patient Factors","volume":"28","author":"McGee","year":"2017","journal-title":"Ann. Oncol. Off. J. Eur. Soc. Med. Oncol."},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1159\/000510098","article-title":"Decision-Making Analysis for Hyperthermic Intraperitoneal Chemotherapy in Ovarian Cancer: A Survey by the Executive Committee of the Peritoneal Surface Oncology Group International (PSOGI)","volume":"99","author":"Steffen","year":"2021","journal-title":"Oncology"},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1007\/s40520-022-02121-z","article-title":"Handgrip Strength Predicts Length of Hospital Stay in an Abdominal Surgical Setting: The Role of Frailty beyond Age","volume":"34","author":"Marano","year":"2022","journal-title":"Aging Clin. Exp. Res."},{"key":"ref_152","first-page":"21","article-title":"Predictors of Morbidity and Mortality in Patients Submitted to Cytoreductive Surgery plus Hyperthermic Intraperitoneal Chemotherapy for Ovarian Carcinomatosis: A Multicenter Study","volume":"6","author":"Accarpio","year":"2020","journal-title":"Pleura Peritoneum"},{"key":"ref_153","doi-asserted-by":"crossref","unstructured":"Boccardi, V., and Marano, L. (2020). The Geriatric Surgery: The Importance of Frailty Identification beyond Chronological Age. Geriatrics, 5.","DOI":"10.3390\/geriatrics5010012"},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"3737","DOI":"10.1200\/JCO.2003.04.187","article-title":"Randomized Trial of Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy versus Systemic Chemotherapy and Palliative Surgery in Patients with Peritoneal Carcinomatosis of Colorectal Cancer","volume":"21","author":"Verwaal","year":"2003","journal-title":"J. Clin. Oncol."},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1007\/s10350-006-0741-9","article-title":"Early Results of Surgery in 123 Patients with Pseudomyxoma Peritonei from a Perforated Appendiceal Neoplasm","volume":"50","author":"Murphy","year":"2007","journal-title":"Dis. Colon Rectum"},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/j.ejso.2010.01.006","article-title":"Pseudomyxoma Peritonei: A French Multicentric Study of 301 Patients Treated with Cytoreductive Surgery and Intraperitoneal Chemotherapy","volume":"36","author":"Elias","year":"2010","journal-title":"Eur. J. Surg. Oncol."},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1093\/annonc\/mdl428","article-title":"A Systematic Review on the Efficacy of Cytoreductive Surgery Combined with Perioperative Intraperitoneal Chemotherapy for Diffuse Malignancy Peritoneal Mesothelioma","volume":"18","author":"Yan","year":"2007","journal-title":"Ann. Oncol. Off. J. Eur. Soc. Med. Oncol."},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"6237","DOI":"10.1200\/JCO.2009.23.9640","article-title":"Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Malignant Peritoneal Mesothelioma: Multi-Institutional Experience","volume":"27","author":"Yan","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/j.ygyno.2020.09.022","article-title":"Current Status of Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for Ovarian Cancer in the United States","volume":"159","author":"Charo","year":"2020","journal-title":"Gynecol. Oncol."},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1093\/annonc\/mdz062","article-title":"ESMO-ESGO Consensus Conference Recommendations on Ovarian Cancer: Pathology and Molecular Biology, Early and Advanced Stages, Borderline Tumours and Recurrent Disease\u2020","volume":"30","author":"Colombo","year":"2019","journal-title":"Ann. Oncol. Off. J. Eur. Soc. Med. Oncol."},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"S182","DOI":"10.21037\/jgo-20-130","article-title":"Narrative Review of Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Patients with Advanced Ovarian Cancer: A Critical Reappraisal of the Current Evidence","volume":"12","author":"Spiliotis","year":"2021","journal-title":"J. Gastrointest. Oncol."},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.1093\/annonc\/mdy198","article-title":"HIPEC: HOPE or HYPE in the Fight against Advanced Ovarian Cancer?","volume":"29","author":"Fotopoulou","year":"2018","journal-title":"Ann. Oncol. Off. J. Eur. Soc. Med. Oncol."},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"525","DOI":"10.5301\/tj.5000623","article-title":"1st Evidence-Based Italian Consensus Conference on Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Peritoneal Carcinosis from Ovarian Cancer","volume":"103","author":"Cavaliere","year":"2017","journal-title":"Tumori"},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.ygyno.2009.03.018","article-title":"Improved Progression-Free and Overall Survival in Advanced Ovarian Cancer as a Result of a Change in Surgical Paradigm","volume":"114","author":"Chi","year":"2009","journal-title":"Gynecol. Oncol."},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/j.ygyno.2007.10.022","article-title":"The Effect of Maximal Surgical Cytoreduction on Sensitivity to Platinum-Taxane Chemotherapy and Subsequent Survival in Patients with Advanced Ovarian Cancer","volume":"108","author":"Eisenhauer","year":"2008","journal-title":"Gynecol. Oncol."},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1097\/IGC.0b013e31821b2568","article-title":"2010 Gynecologic Cancer InterGroup (GCIG) Consensus Statement on Clinical Trials in Ovarian Cancer: Report from the Fourth Ovarian Cancer Consensus Conference","volume":"21","author":"Stuart","year":"2011","journal-title":"Int. J. Gynecol. Cancer"},{"key":"ref_167","doi-asserted-by":"crossref","unstructured":"Van de Laar, R., Zusterzeel, P.L.M., Van Gorp, T., Buist, M.R., Van Driel, W.J., Gaarenstroom, K.N., Arts, H.J.G., Van Huisseling, J.C.M., Hermans, R.H.M., and Pijnenborg, J.M.A. (2014). Cytoreductive Surgery Followed by Chemotherapy versus Chemotherapy Alone for Recurrent Platinum-Sensitive Epithelial Ovarian Cancer (SOCceR Trial): A Multicenter Randomised Controlled Study. BMC Cancer, 14.","DOI":"10.1186\/1471-2407-14-22"},{"key":"ref_168","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1200\/JCO.2002.20.5.1248","article-title":"Survival Effect of Maximal Cytoreductive Surgery for Advanced Ovarian Carcinoma during the Platinum Era: A Meta-Analysis","volume":"20","author":"Bristow","year":"2002","journal-title":"J. Clin. Oncol."},{"key":"ref_169","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1186\/1477-7819-11-64","article-title":"Depth of Colorectal-Wall Invasion and Lymph-Node Involvement as Major Outcome Factors Influencing Surgical Strategy in Patients with Advanced and Recurrent Ovarian Cancer with Diffuse Peritoneal Metastases","volume":"11","author":"Cardi","year":"2013","journal-title":"World J. Surg. Oncol."},{"key":"ref_170","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1002\/(SICI)1097-0142(20000115)88:2<389::AID-CNCR21>3.0.CO;2-W","article-title":"Primary Cytoreductive Surgery with Rectosigmoid Colon Resection for Patients with Advanced Epithelial Ovarian Carcinoma","volume":"88","author":"Scarabelli","year":"2000","journal-title":"Cancer"},{"key":"ref_171","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1016\/j.ygyno.2006.03.051","article-title":"What Is the Optimal Goal of Primary Cytoreductive Surgery for Bulky Stage IIIC Epithelial Ovarian Carcinoma (EOC)?","volume":"103","author":"Chi","year":"2006","journal-title":"Gynecol. Oncol."},{"key":"ref_172","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1016\/S0002-9378(94)70090-7","article-title":"The Effect of Diameter of Largest Residual Disease on Survival after Primary Cytoreductive Surgery in Patients with Suboptimal Residual Epithelial Ovarian Carcinoma","volume":"170","author":"Hoskins","year":"1994","journal-title":"Am. J. Obstet. Gynecol."},{"key":"ref_173","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1006\/gyno.2001.6313","article-title":"Procedures Required to Accomplish Complete Cytoreduction of Ovarian Cancer: Is There a Correlation with \u201cBiological Aggressiveness\u201d and Survival?","volume":"82","author":"Eisenkop","year":"2001","journal-title":"Gynecol. Oncol."},{"key":"ref_174","doi-asserted-by":"crossref","first-page":"3793","DOI":"10.2174\/138161212802002616","article-title":"Survival Benefit of Adding Hyperthermic IntraPEritoneal Chemotherapy (HIPEC) at the Different Time-Points of Treatment of Ovarian Cancer: Review of Evidence","volume":"18","author":"Mulier","year":"2012","journal-title":"Curr. Pharm. Des."},{"key":"ref_175","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1245\/s10434-016-5686-1","article-title":"Cytoreduction (Peritonectomy Procedures) Combined with Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Advanced Ovarian Cancer: Retrospective Italian Multicenter Observational Study of 511 Cases","volume":"24","author":"Garofalo","year":"2017","journal-title":"Ann. Surg. Oncol."},{"key":"ref_176","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.ejogrb.2009.07.016","article-title":"Histological Response Is Not a Prognostic Factor after Neoadjuvant Chemotherapy in Advanced-Stage Ovarian Cancer with No Residual Disease","volume":"147","author":"Ferron","year":"2009","journal-title":"Eur. J. Obstet. Gynecol. Reprod. Biol."},{"key":"ref_177","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1093\/annonc\/mdw007","article-title":"Identification of High-Grade Serous Ovarian Cancer MiRNA Species Associated with Survival and Drug Response in Patients Receiving Neoadjuvant Chemotherapy: A Retrospective Longitudinal Analysis Using Matched Tumor Biopsies","volume":"27","author":"Petrillo","year":"2016","journal-title":"Ann. Oncol. Off. J. Eur. Soc. Med. Oncol."},{"key":"ref_178","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.ygyno.2013.12.002","article-title":"Neoadjuvant Chemotherapy with Six Cycles of Carboplatin and Paclitaxel in Advanced Ovarian Cancer Patients Unsuitable for Primary Surgery: Safety and Effectiveness","volume":"132","author":"Sanchez","year":"2014","journal-title":"Gynecol. Oncol."},{"key":"ref_179","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1016\/j.ygyno.2016.01.008","article-title":"Neoadjuvant Chemotherapy and Primary Debulking Surgery Utilization for Advanced-Stage Ovarian Cancer at a Comprehensive Cancer Center","volume":"140","author":"Mueller","year":"2016","journal-title":"Gynecol. Oncol."},{"key":"ref_180","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1002\/jso.25703","article-title":"Upfront Debulking Surgery versus Interval Debulking Surgery for Advanced Tubo-Ovarian High-Grade Serous Carcinoma and Diffuse Peritoneal Metastases Treated with Peritonectomy Procedures plus HIPEC","volume":"120","author":"Biacchi","year":"2019","journal-title":"J. Surg. Oncol."},{"key":"ref_181","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.ygyno.2012.01.001","article-title":"Re: \u201cCytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy as Upfront Therapy for Advanced Epithelial Ovarian Cancer: Multi-Institutional Phase II Trial.\u201d\u2014Proposal of a Clinical Trial of Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy in Advanced Ovarian Cancer, the CHORINE Study","volume":"125","author":"Ansaloni","year":"2012","journal-title":"Gynecol. Oncol."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/14\/23\/6010\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T01:35:07Z","timestamp":1760146507000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/14\/23\/6010"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,6]]},"references-count":181,"journal-issue":{"issue":"23","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["cancers14236010"],"URL":"https:\/\/doi.org\/10.3390\/cancers14236010","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,6]]}}}